Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
Abstract Background Antihormonal treatment for hormone receptor (HR) positive breast cancer has highly beneficial effects on both recurrence rates and survival. We investigate adherence and persistence in this group of patients. Methods The study population comprised 1192 patients with HR-positive b...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10362-4 |
| _version_ | 1811315151937208320 |
|---|---|
| author | Ida Dragvoll Anna M. Bofin Håvard Søiland Gunnar Taraldsen Monica Jernberg Engstrøm |
| author_facet | Ida Dragvoll Anna M. Bofin Håvard Søiland Gunnar Taraldsen Monica Jernberg Engstrøm |
| author_sort | Ida Dragvoll |
| collection | DOAJ |
| description | Abstract Background Antihormonal treatment for hormone receptor (HR) positive breast cancer has highly beneficial effects on both recurrence rates and survival. We investigate adherence and persistence in this group of patients. Methods The study population comprised 1192 patients with HR-positive breast cancer who were prescribed adjuvant antihormonal treatment from 2004 to 2013. Adherence was defined as a medical possession ratio (MPR) of ≥80. Results Of the 1192 included patients, 903 (75.8%) were adherent and 289 (24.2%) were non-adherent. Primary non-adherence was seen in 101 (8.5%) patients. The extremes of age (< 40 and ≥ 80 years) were associated with poor adherence. Patients with metastasis to axillary lymph nodes and those who received radiotherapy and/or chemotherapy were more likely to be adherent. Better adherence was also shown for those who switched medication at 2 years after diagnosis. Primary non-adherence seems to be associated with cancers with a good prognosis. Conclusion Adherence to antihormonal therapy for breast cancer is suboptimal. Primary non-adherence occurs among patients with a relatively good prognosis. Non-adherent patients tend to terminate their antihormonal therapy in the initial part of the treatment period. Targeted interventions to improve adherence should be focused on the first part of the treatment period. |
| first_indexed | 2024-04-13T11:25:05Z |
| format | Article |
| id | doaj.art-4803e45092274394b5c6481b3d887caf |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T11:25:05Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-4803e45092274394b5c6481b3d887caf2022-12-22T02:48:42ZengBMCBMC Cancer1471-24072022-12-0122111210.1186/s12885-022-10362-4Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancerIda Dragvoll0Anna M. Bofin1Håvard Søiland2Gunnar Taraldsen3Monica Jernberg Engstrøm4Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU)Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU)Department of Research, Stavanger University HospitalDepartment of Mathematical Sciences, Faculty of Information Technology and Electrical Engineering, Norwegian University of Science and Technology (NTNU)Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU)Abstract Background Antihormonal treatment for hormone receptor (HR) positive breast cancer has highly beneficial effects on both recurrence rates and survival. We investigate adherence and persistence in this group of patients. Methods The study population comprised 1192 patients with HR-positive breast cancer who were prescribed adjuvant antihormonal treatment from 2004 to 2013. Adherence was defined as a medical possession ratio (MPR) of ≥80. Results Of the 1192 included patients, 903 (75.8%) were adherent and 289 (24.2%) were non-adherent. Primary non-adherence was seen in 101 (8.5%) patients. The extremes of age (< 40 and ≥ 80 years) were associated with poor adherence. Patients with metastasis to axillary lymph nodes and those who received radiotherapy and/or chemotherapy were more likely to be adherent. Better adherence was also shown for those who switched medication at 2 years after diagnosis. Primary non-adherence seems to be associated with cancers with a good prognosis. Conclusion Adherence to antihormonal therapy for breast cancer is suboptimal. Primary non-adherence occurs among patients with a relatively good prognosis. Non-adherent patients tend to terminate their antihormonal therapy in the initial part of the treatment period. Targeted interventions to improve adherence should be focused on the first part of the treatment period.https://doi.org/10.1186/s12885-022-10362-4Breast cancerAntihormonal treatmentTamoxifenAromatase inhibitorsAdherencePrimary non-adherence |
| spellingShingle | Ida Dragvoll Anna M. Bofin Håvard Søiland Gunnar Taraldsen Monica Jernberg Engstrøm Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer BMC Cancer Breast cancer Antihormonal treatment Tamoxifen Aromatase inhibitors Adherence Primary non-adherence |
| title | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer |
| title_full | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer |
| title_fullStr | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer |
| title_full_unstemmed | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer |
| title_short | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer |
| title_sort | predictors of adherence and the role of primary non adherence in antihormonal treatment of breast cancer |
| topic | Breast cancer Antihormonal treatment Tamoxifen Aromatase inhibitors Adherence Primary non-adherence |
| url | https://doi.org/10.1186/s12885-022-10362-4 |
| work_keys_str_mv | AT idadragvoll predictorsofadherenceandtheroleofprimarynonadherenceinantihormonaltreatmentofbreastcancer AT annambofin predictorsofadherenceandtheroleofprimarynonadherenceinantihormonaltreatmentofbreastcancer AT havardsøiland predictorsofadherenceandtheroleofprimarynonadherenceinantihormonaltreatmentofbreastcancer AT gunnartaraldsen predictorsofadherenceandtheroleofprimarynonadherenceinantihormonaltreatmentofbreastcancer AT monicajernbergengstrøm predictorsofadherenceandtheroleofprimarynonadherenceinantihormonaltreatmentofbreastcancer |